A subscription to JoVE is required to view this content. Sign in or start your free trial.
Myocardial gene therapy for ischemic heart disease holds great promise for future therapeutics. Here, we introduce a large animal model for evaluating the efficacy of gene therapy in the ischemic heart.
Coronary artery disease is one of the significant causes of mortality and morbidity worldwide. Despite the progression of current therapeutics, a considerable proportion of coronary artery disease patients remain symptomatic. Gene therapy-mediated therapeutic angiogenesis offers a novel therapeutic method for improving myocardial perfusion and relieving symptoms. Gene therapy with different angiogenic factors has been studied in few clinical trials. Due to the novelty of the method, the progress of myocardial gene therapy is a continuous path from bench to bedside. Therefore, large animal models are needed for evaluating the safety and efficacy. The more the large animal model identifies the original disease and the endpoints used in clinics, the more predictable outcomes are from clinical trials. Here, we introduce a large animal model for evaluating the efficacy of the gene therapy in the ischemic porcine heart. We use clinically relevant imaging methods such as ultrasound imaging and 15H2O-PET. For targeting the gene transfers into the desired area, electroanatomical mapping is used. The aim of this method is: (1) to mimic chronic coronary artery disease, (2) to induce therapeutic angiogenesis at hypoxic areas of the heart, and (3) to evaluate the safety and efficacy of the gene therapy by using relevant endpoints.
Coronary artery disease is accountable for the vast proportion of mortality and disease burden worldwide1. Current treatment strategies are percutaneous interventions, pharmacological treatment, and bypass surgery2. However, despite the progression of these current therapeutics, many patients suffer from so-called refractory angina, underlining the unmet need for novel treatment approaches3. Gene therapy-mediated therapeutic angiogenesis could target this patient group.
Myocardial gene therapy is most often delivered by using different viral vectors, most commonly replication-deficient adenovirus4. As therapeutic genes, various angiogenic growth factors are used. The most substantially studied angiogenic growth factors are the vascular endothelial growth factors (VEGFs) that mediate their angiogenic signaling through vascular endothelial growth factor receptors (VEGFRs) and their co-receptors5. Several clinical trials have proved the benefit and safety of cardiac gene therapy and made this novel treatment method a realistic option for treating ischemic heart diseases6,7. However, this concept still needs enhancement of the therapeutic genes and viral vectors put to the test in large animal models before entering the clinics. The pig has been frequently used as a laboratory animal since its heart is very similar to the human heart. The size of the cardiovascular system of a pig allows the usage of similar catheter inventions as used in humans. All imaging modalities available for humans can be used in pigs8.
There are several large animal models for chronic ischemia. The most commonly used is the ameroid constrictor model9,10,11. The downside of this method is the invasiveness since thoracotomy is needed to access the coronary vasculature. Previously in our group, a mini-invasive bottleneck stent model for chronic myocardial ischemia has been developed12. This method is also used in this manuscript to induce myocardial ischemia.
The usability of ultrasound imaging has evolved substantially despite the age of the imaging modality. For example, myocardial strain is still mainly in research usage due to its novelty. Myocardial strain reflects changes in the contractile function of the heart better than the traditional M-mode ejection fraction measurement13. Thus, here in the large animal model, myocardial strain measurement is utilized. To evaluate the function of the heart, cardiac output is also measured by cine imaging of the left ventricle during angiography. Cardiac output is measured both at rest and under dobutamine-induced stress to evaluate myocardial function under stress.
In addition to the measurements of the heart function, information on myocardial perfusion is essential in gene therapy studies aiming at therapeutic angiogenesis. In this animal model, animals are imaged with 15O-labeled radiowater positron emission tomography (15H2O-PET) as this is the golden standard for measuring myocardial perfusion. 15H2O-PET has been previously validated for measuring perfusion of ischemic porcine heart14.
Thus, the methods and modalities mentioned above constitute an excellent perspective for evaluating the efficacy of gene therapy in the ischemic heart.
The experiments presented here are performed using about 10-week-old female domestic pigs and are approved by the Animal Experiment Board in Finland. Animals weigh 30-40 kg at the beginning of the protocol, allowing the same procedural equipment and imaging modalities as possible for humans. Chronic ischemia is induced 14 days before the gene transfer, and the follow-up time after the gene transfer depends on the viral vector used. The study protocol is shown in Figure 1. This protocol can be used to perform adenoviral or AAV-mediated gene therapy injections. The time of sample collection has to be adjusted to the transgene expression peak, which depends on the viral vector used. For example, when performing adenoviral gene transfers, the time of the sample collection is set to 6 days after the gene transfer.
1. Medication
2. Transthoracic echocardiography
3. Endovascular operations under fluoroscopic guidance
4. PET imaging
NOTE: One day before the gene transfer, perform rest and stress 15O-labeled radiowater PET/CT scans (requires hospital environment and radiological technicians).
5. Gene transfer
6. Euthanasia and sample collection
NOTE: After the coronary angiogram and ejection fraction measurements described in steps 3.4.1 and 3.5.2, respectively, administer 50 mL of saturated potassium chloride intravenously to the anesthetized pig.
7. Sample storing
The success of the ischemia operation can be confirmed with this protocol by coronary angiogram and by determining the hypokinetic area by transthoracic ultrasound (Figure 1) before proceeding to the gene delivery. The state of the coronary occlusion can be evaluated by coronary angiogram, and the electroanatomical mapping ensures the ischemic and hibernating areas.
The efficacy of the gene therapy can be analyzed by measuring the circumferential strain, ejection ...
The timepoints of this protocol may be modified according to the viral vector used. Also, the immunohistological analyses may be selected according to the therapeutic gene. It is also possible to add more timepoints and endpoints to the protocol if needed.
This protocol comprises stages, which are essential to succeed and impossible to correct afterward. First, if one fails to induce appropriate ischemia, the animal must be excluded from further procedures and analyses. Standardization of the ...
The authors declare no conflicts of interest.
The authors would like to thank Maria Hedman, Tiina Laitinen, Tomi Laitinen, Pekka Poutiainen, Annika Viren, and Severi Sormunen for assistance and permitting 15O-PET imaging at Kuopio University Hospital; and Heikki Karhunen, Minna Törrönen, and Riikka Venäläinen from National Laboratory Animal Center for their assistance in animal work.
This study is supported by grants from Finnish Academy, ERC, and CardioReGenix EU Horizon 2020 grant.
Name | Company | Catalog Number | Comments |
1% PFA | VWR | VWRC28794.295 | Prepared from paraformaldehyde powder |
15 % sucrose | VWR | VWRC27480.294 | Prepared from solid sucrose |
4% PFA | VWR | VWRC28794.295 | Prepared from paraformaldehyde powder |
5 F pigtail catheter | Cordis | 534-550S | |
6 F catheter AR2 | Cordis | 670-112-00 | |
6 F introducer sheath | Cordis | 504-606X | |
8 F introducer sheath | Cordis | 504-608X | |
Acetylsalicylic acid | Varying producer | ||
Amiodarone | Varying producer | ||
Angiographic station | GE Healthcare | ||
Angiolaboratory set | Mölnlycke | designed for the needs of our angiolaboratory, contains sterile drapes, cups and swabs | |
Bisoprolol | Varying producer | ||
Cefuroxime | Varying producer | ||
Clopidogrel | Varying producer | ||
Coroflex Blue stent | B.Braun Medical | 5029012 | Catalog number depends on stent size |
Crile forceps | |||
Cyclotron | GE Healthcare | ||
Dobutamine | Varying producer | ||
Electroanatomical mapping system | Biologics Delivery Systems, Johnson & Johnson company | ||
Enoxaparin | Varying producer | ||
Fentanyl | Varying producer | ||
Intramyocardial injection catheter | Johnson & Johnson | ||
Iodine contrast agent | Iomeron | ||
Kitchen knife | Varying producer | ||
Lidocaine | Varying producer | ||
Liquid nitrogen | Varying producer | ||
MgSO4 | Varying producer | ||
Needle 18 G | Cordis | 12-004943 | |
Perfusion pump | |||
PET-CT scanner | Siemens Healthcare | ||
Polytetrafluoroethylene tube | |||
Propofol | Varying producer | ||
Scalpel no 11 | VWR | SWAN0503 | |
Sublingual dinitrate | Takeda | ||
Ultrasound machine | Philips |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved